arrow
J

Jaskaran Singh

Takeda Pharmaceutical Company Ltd
H指数:38
被引数:1.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Corrigendum to “exploratory anchor-based analyses to determine minimal clinically important differences for the brief assessment of cognition in schizophrenia and the schizophrenia cognition rating scale” [Schizophr. Res. 2026 July 25. doi:10.1016/j.schres.2026.07.021. Epub ahead of print]

对“探索性基于锚定的分析以确定精神分裂症认知简明评估和精神分裂症认知评定量表的最小临床重要差异”的勘误 [Schizophr. Res. 2026 July 25. doi:10.1016/j.schres.2026.07.021. Epub ahead of print]

2026-08-180
PRE
Exploratory anchor-based analyses to determine minimal clinically important differences for the Brief Assessment of Cognition in Schizophrenia and the Schizophrenia Cognition Rating Scale

探索性锚定分析以确定精神分裂症认知简明评估和精神性认知评级量表的最低临床重要差异

2026-07-011
PRE
A phase 2 randomized controlled trial of luvadaxistat in treatment of adults with cognitive impairment associated with schizophrenia: results from the ERUDITE study

鲁瓦达克西STAT在治疗伴有认知障碍的精神分裂症成人中的2期随机对照试验:ERUDITE研究的结果

2026-04-240
OAAI
Towards Enhancing Drug Development Methodology to Treat Cognitive Impairment Associated With Schizophrenia and Other Neuropsychiatric Conditions: Insights From 2 Decades of Clinical Trials
2025-02-210
OAAI
Response to Commentaries

对评论的答复

2025-01-250
OAAI